_256_384.jpg)
News | February 26, 2021
Bayer delivers robust performance despite pandemic
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
